Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer

Published on Feb 12, 2021in Thyroid5.227
· DOI :10.1089/THY.2020.0276
Carlotta Giani9
Estimated H-index: 9
(UniPi: University of Pisa),
Laura Valerio9
Estimated H-index: 9
+ 14 AuthorsRossella Elisei68
Estimated H-index: 68
(UniPi: University of Pisa)
Source
Abstract
References0
Newest
Cited By5
Newest
#1Naoki Fukuda (Hokkaido University)H-Index: 5
#2Shunji Takahashi (JFCR: Japanese Foundation for Cancer Research)H-Index: 27
Differentiated thyroid cancer is usually a slow-growing disease, even if the patients develop distant metastasis. For recurrent or metastatic disease, radioactive iodine therapy is a standard treatment. However, the disease gradually progresses in some of the patients and can ultimately develop into life-threatening conditions. For patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RR-DTC), multi-kinase inhibitors (MKIs) including sorafenib and lenvatinib prol...
Source
#1Francesca Platini (University of Milan)H-Index: 4
#2Stefano Cavalieri (University of Milan)H-Index: 8
Last. Laura D. Locati (University of Milan)H-Index: 30
view all 12 authors...
PURPOSE Radioactive-iodine (RAI)-resistant differentiated thyroid cancer (DTC) patients benefit from multi-kinase inhibitors (MKIs), such as lenvatinib. Incidence of treatment-related (TR) late toxicities has been not yet described. METHODS From January 2015 to June 2019 we retrospectively reviewed clinical records of patients with RAI-resistant DTC treated with lenvatinib at Istituto Nazionale dei Tumori (Milan, Italy). New side effect of any grade, appeared after 12 months of lenvatinib, was d...
Source
Differentiated thyroid cancers (DTC) are commonly and successfully treated with total thyroidectomy plus/minus radioiodine therapy (RAI). Medullary thyroid cancer (MTC) is only treated with surgery but only intrathyroidal tumors are cured. The worst prognosis is for anaplastic (ATC) and poorly differentiated thyroid cancer (PDTC). Whenever a local or metastatic advanced disease is present, other treatments are required, varying from local to systemic therapies. In the last decade, the efficacy o...
Source
#1Frederik A. Verburg (EUR: Erasmus University Rotterdam)H-Index: 9
#2Holger Amthauer (Humboldt University of Berlin)H-Index: 40
Last. Matthias SchottH-Index: 110
view all 16 authors...
Notwithstanding regulatory approval of lenvatinib and sorafenib to treat radioiodine-refractory differentiated thyroid carcinoma (RAI-R DTC), important questions and controversies persist regarding this use of these tyrosine kinase inhibitors (TKIs). RAI-R DTC experts from German tertiary referral centers convened to identify and explore such issues; this paper summarizes their discussions. One challenge is determining when to start TKI therapy. Decision-making should be shared between patients ...
Source
#1Martin Schlumberger (Institut Gustave Roussy)H-Index: 92
#2Sophie Leboulleux (Institut Gustave Roussy)H-Index: 60
Considerable changes have occurred in the management of differentiated thyroid cancer (DTC) during the past four decades, based on improved knowledge of the biology of DTC and on advances in therapy, including surgery, the use of radioactive iodine (radioiodine), thyroid hormone treatment and availability of recombinant human TSH. Improved diagnostic tools are available, including determining serum levels of thyroglobulin, neck ultrasonography, imaging (CT, MRI, SPECT-CT and PET-CT), and prognos...
3 CitationsSource
#1Tommaso Porcelli (University of Naples Federico II)H-Index: 5
#2Cristina Luongo (University of Naples Federico II)H-Index: 10
Last. Domenico Salvatore (University of Naples Federico II)H-Index: 32
view all 9 authors...
Purpose The efficacy of lenvatinib for advanced and progressive radioactive iodine refractory differentiated thyroid cancer is well established. Herein, we retrospectively evaluated the long-term safety and efficacy of lenvatinib in 23 patients treated at a single Institution. Methods Clinical data of all patients treated for a differentiated thyroid cancer with lenvatinib from April 2015 to September 2020 were retrospectively analyzed. Results A total of 23 patients were included. In all, 21 pa...
Source